Journals / Cukurova Medical Journal / 2018 / Cilt: 43 Sayı: Ek 1

Effect of ACSL4 gene polymorphism (rs7886473) on metabolic syndrome and lipid levels

ACSL4 gen polimorfizminin (rs7886473) metabolik sendrom ve lipid düzeyleri üzerine etkisi

Pages
151–157
Publication Date
2018-12-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this instance, this study is not enough to determine whether ACSL4 gene is not effective on metabolic syndrome and/or lipid levels.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Acyl-CoA synthetase long-chain family member 4 (ACSL4) is thought to be related with obesity and metabolic syndrome via lipid metabolism.
📊
Key Findings & Data:We aimed to investigate the effect of the single nucleotide polymorphism (SNP) rs7886473, which is a common intron variant of ACSL4 gene on metabolic syndrome and lipids in Turkish society.Materials and Methods: Metabolic syndrome (n=556) and non-metabolic syndrome (n=520) patients according to the modified NCEP ATPIII metabolic syndrome criterias were included in the study.
💡
Conclusion & Impact:In this instance, this study is not enough to determine whether ACSL4 gene is not effective on metabolic syndrome and/or lipid levels.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:ACSL4 · gen polimorfizmi · lipid

Abstract

Purpose: Acyl-CoA synthetase long-chain family member 4 (ACSL4) is thought to be related with obesity and metabolic syndrome via lipid metabolism. We aimed to investigate the effect of the single nucleotide polymorphism (SNP) rs7886473, which is a common intron variant of ACSL4 gene on metabolic syndrome and lipids in Turkish society.Materials and Methods: Metabolic syndrome (n=556) and non-metabolic syndrome (n=520) patients according to the modified NCEP ATPIII metabolic syndrome criterias were included in the study. SNPs were genotyped with Roche Light Cycler 480 Real-Time PCR and then compared between groups.Results: There was no significant difference in the genotype frequencies of the ACSL4 gene polymorphism (rs7886473) between the metabolic syndrome and the non-metabolic syndrome patient groups. There were no significant differences in serum total cholesterol, HDL, LDL and triglyceride levels between GG and AA genotypes either in men or women.Conclusion: This study showed that ACSL4 gene polymorphism (rs7886473) has no effect on metabolic syndrome and serum lipid levels. However, only one common SNP on the ACSL4 gene was examined in our study. In this instance, this study is not enough to determine whether ACSL4 gene is not effective on metabolic syndrome and/or lipid levels.

Özet

Amaç: Lipid metabolizması üzerinden obezite ve metabolik sendromla ilişkisi olabileceğini düşündüğümüz ACSL4 geninin sık görülen rs7886473 A>G polimorfizminin Türk toplumunda metabolik sendrom ve lipid düzeyleri üzerindeki etkisini araştırmayı amaçladık.Gereç ve Yöntem: Çalışmamıza, Türkiye genelinde takip edilen ve modifiye edilmiş NCEP ATPIII Metabolik Sendrom tanı kriterlerine göre 556 metabolik sendrom olan ve 520 metabolik sendrom olmayan erişkin birey dahil edildi. Metabolik sendrom olan ve olmayan bireylerin ACSL4 gen polimorfizmi Roche Light Cycler 480 Real-Time PCR ile genotiplendi ve karşılaştırıldı.Bulgular: Metabolik sendrom olan ve metabolik sendrom olmayan bireyler arasında ACSL4 rs7886473 genotip dağılımları arasında anlamlı bir farklılık bulunmadı. Tüm erkeklerin ACSL4 rs7886473 polimorfizmine göre serum total kolesterol, HDL, LDL ve trigliserid düzeyleri karşılaştırıldığında; GG ve AA genotipleri arasında anlamlı bir farklılık bulunmadı. Benzer şekilde tüm kadınlarda da anlamlı farklılık bulunmadı.Sonuç: Bu çalışma, ACSL4 geni açısından incelemiş olduğumuz rs7886473 gen polimorfizminin metabolik sendrom ve serum lipid düzeyleri üzerine etkisi olmadığını gösterdi. Ancak çalışmamızda incelenmiş olan ACSL4 geninde yaygın görülen yalnızca bir polimorfizmdir. Bu durum ACSL4 geninin lipid metabolizması ve/veya metabolik sendrom üzerine etkili olmadığını değerlendirmek için tek başına yeterli değildir.

🔖

Cite This Article

VURGUN, E., DİKER, İ. Y., ÇOBAN, N., GEYİK, F., GÜVEN, G., ÜNALTUNA, N. E. (2018). Effect of ACSL4 gene polymorphism (rs7886473) on metabolic syndrome and lipid levels. Cukurova Medical Journal, Cilt: 43 Sayı: Ek 1, 151–157. https://ajindex.com/articles/56515

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
  2. Raz I, Eldor R, Cernea S, Shafrir E. Diabetes: Insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res Rev 2005;21:3-14.
  3. Soupene E, Kuypers FA. Mammalian long-chain acyl-CoA synthetases. Exp Biol Med (Maywood) 2008;233:507-21.
  4. Grundy SM, Hypertriglyceridemia, Insulin Resistance, and the Metabolic Syndrome. The American Journal of Cardiology 1999 83;9:25-9.
  5. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002;87:3023-28.
  6. Ryysy L, Hakkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000;49:749-58.
  7. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006;49:755-65.
  8. Adiels M, Westerbacka J, Soro-Paavonen A, Hakkinen AM, Vehkavaara S, Caslake MJ, et al. Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia 2007;50:2356-65.
  9. Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007;92:3490-97.
  10. Suzuki H, Kawarabayasi Y, Kondo J, Abe T, Nishikawa K, Kimura S, et al. Structure and regulation of rat long-chain acyl-CoA synthetase. J Biol Chem 1990;265:8681-85.
  11. Lewin TM, Van Horn CG, Krisans SK, Coleman RA. Rat liver acyl-CoA synthetase 4 is a peripheral-membrane protein located in two distinct subcellular organelles, peroxisomes, and mitochondrial-associated membrane. Arch Biochem Biophys 2002;404:263-70.
  12. Kim JH, Lewin TM, Coleman RA. Expr